Priya Engel, Caitlyn Kellogg, Sogol Stephanie Javadi, Jan Smogorzewski
<p>Psoriasis, a chronic inflammatory skin condition, may be linked to COVID-19 risk. A 2022 United Kingdom study found increased COVID-19 morbidity and mortality in those with immune-mediated inflammatory diseases, including psoriasis [<span>1</span>]. Additionally, there is growing concern that SARS-CoV-2 infections might trigger or worsen chronic immune-mediated diseases [<span>2</span>]. To our knowledge, recent studies concerning the possible associations between psoriasis and COVID-19 in a large-scale, nationally representative population of the United States have been lacking.</p><p>We utilised the 2023 National Health Interview Survey to model a nationally representative sample. Our analysis included 29,156 adults (≥ 18 years). The primary outcome variables were history of psoriasis and history of COVID-19 infection. Multivariable logistic regression analyses were constructed with STATA/BE 18.5 and adjusted for confounders including age, education, race, income, sex, cigarette smoking status, body mass index (BMI), and arthritis.</p><p>In our study, roughly 3% (weighted) of the respondents reported a history of psoriasis. Of those with psoriasis, 60.1% reported having had COVID-19 infection compared to 55.4% of individuals without psoriasis (<i>p</i> < 0.05; Table 1).</p><p>Further analysis demonstrated a statistically significant association between psoriasis and COVID-19 infection (AOR 1.19; 95% CI: 1.01–1.41; <i>p</i> < 0.05) after adjusting for confounders. Individuals with psoriasis had 19% greater odds of having COVID-19 infection compared to individuals without psoriasis (Table 2). In males, psoriasis was associated with increased odds of COVID-19 infection (AOR: 1.37, 95% CI: 1.06–1.76; <i>p</i> < 0.05) compared to male respondents without psoriasis. There was no significant difference among females with and without psoriasis. Non-Hispanic Black individuals with psoriasis reported double the odds of COVID-19 infection compared to those without psoriasis (AOR: 2.12, 95% CI: 1.02–4.40. <i>p</i> < 0.05). Finally, psoriasis was linked to a 19% higher likelihood of COVID-19 infection in individuals not using immunosuppressants (AOR: 1.19, 95% CI: 1.00–1.42; <i>p</i> = 0.05). However, this increased risk is not seen in patients taking immunosuppressants, where the likelihood of COVID-19 infection is comparable between those with and without psoriasis.</p><p>Overall, our findings suggest that psoriasis was associated with a higher risk of COVID-19 infection, specifically in males and non-Hispanic Black individuals. Clinicians should be aware that the risk of developing COVID-19 is not uniform across all patients with psoriasis. Our results indicate that individuals with psoriasis who were not taking immunosuppressants had a higher likelihood of COVID-19 infection. This increased risk, however, was not observed in those using immunosuppressants. While this finding suggests a potential difference in COVID-19 risk between these g
{"title":"Association Between Psoriasis and COVID-19 in the 2023 National Health Interview Survey","authors":"Priya Engel, Caitlyn Kellogg, Sogol Stephanie Javadi, Jan Smogorzewski","doi":"10.1002/jvc2.70045","DOIUrl":"https://doi.org/10.1002/jvc2.70045","url":null,"abstract":"<p>Psoriasis, a chronic inflammatory skin condition, may be linked to COVID-19 risk. A 2022 United Kingdom study found increased COVID-19 morbidity and mortality in those with immune-mediated inflammatory diseases, including psoriasis [<span>1</span>]. Additionally, there is growing concern that SARS-CoV-2 infections might trigger or worsen chronic immune-mediated diseases [<span>2</span>]. To our knowledge, recent studies concerning the possible associations between psoriasis and COVID-19 in a large-scale, nationally representative population of the United States have been lacking.</p><p>We utilised the 2023 National Health Interview Survey to model a nationally representative sample. Our analysis included 29,156 adults (≥ 18 years). The primary outcome variables were history of psoriasis and history of COVID-19 infection. Multivariable logistic regression analyses were constructed with STATA/BE 18.5 and adjusted for confounders including age, education, race, income, sex, cigarette smoking status, body mass index (BMI), and arthritis.</p><p>In our study, roughly 3% (weighted) of the respondents reported a history of psoriasis. Of those with psoriasis, 60.1% reported having had COVID-19 infection compared to 55.4% of individuals without psoriasis (<i>p</i> < 0.05; Table 1).</p><p>Further analysis demonstrated a statistically significant association between psoriasis and COVID-19 infection (AOR 1.19; 95% CI: 1.01–1.41; <i>p</i> < 0.05) after adjusting for confounders. Individuals with psoriasis had 19% greater odds of having COVID-19 infection compared to individuals without psoriasis (Table 2). In males, psoriasis was associated with increased odds of COVID-19 infection (AOR: 1.37, 95% CI: 1.06–1.76; <i>p</i> < 0.05) compared to male respondents without psoriasis. There was no significant difference among females with and without psoriasis. Non-Hispanic Black individuals with psoriasis reported double the odds of COVID-19 infection compared to those without psoriasis (AOR: 2.12, 95% CI: 1.02–4.40. <i>p</i> < 0.05). Finally, psoriasis was linked to a 19% higher likelihood of COVID-19 infection in individuals not using immunosuppressants (AOR: 1.19, 95% CI: 1.00–1.42; <i>p</i> = 0.05). However, this increased risk is not seen in patients taking immunosuppressants, where the likelihood of COVID-19 infection is comparable between those with and without psoriasis.</p><p>Overall, our findings suggest that psoriasis was associated with a higher risk of COVID-19 infection, specifically in males and non-Hispanic Black individuals. Clinicians should be aware that the risk of developing COVID-19 is not uniform across all patients with psoriasis. Our results indicate that individuals with psoriasis who were not taking immunosuppressants had a higher likelihood of COVID-19 infection. This increased risk, however, was not observed in those using immunosuppressants. While this finding suggests a potential difference in COVID-19 risk between these g","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 5","pages":"1218-1220"},"PeriodicalIF":0.5,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70045","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145625744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christina M. W. Eecen, Jolijn C. de Brabander - Bethlem, Peter Velthuis, Mengzhen Liu, Bridget Riley-Gillis, Jean-Philippe Therrien, Tamar Nijsten, Luba M. Pardo